Chronic neutrophilic leukemia medical therapy: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
m (Bot: Removing from Primary care) |
||
| (33 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic neutrophilic leukemia}} | {{Chronic neutrophilic leukemia}} | ||
{{CMG}}; {{AE}} {{Homa}}; {{GRR}} {{Nat}} | |||
* | ==Overview== | ||
*Hydroxyurea | There is no standard medical treatment for chronic neutrophilic leukemia (CNL). Although, [[Hydroxyurea]], [[Ruxolitinib]], [[Interferon]], [[Thalidomide]], [[Cladribine]] and [[Imatinib]] are some options that are used in [[patients]] with CNL. | ||
* | |||
* | {{Chronic neutrophilic leukemia}} | ||
* | ==Medical Therapy== | ||
*Thalidomide | There is no established treatment for patients with CNL. However, following options may be useful in treatment of patients with CNL:<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="SzuberTefferi2018">{{cite journal|last1=Szuber|first1=Natasha|last2=Tefferi|first2=Ayalew|title=Chronic neutrophilic leukemia: new science and new diagnostic criteria|journal=Blood Cancer Journal|volume=8|issue=2|year=2018|issn=2044-5385|doi=10.1038/s41408-018-0049-8}}</ref><ref name="pmid289288">{{cite journal| author=You W, Weisbrot IM| title=Chronic neutrophilic leukemia. Report of two cases and review of the literature. | journal=Am J Clin Pathol | year= 1979 | volume= 72 | issue= 2 | pages= 233-42 | pmid=289288 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=289288 }} </ref> | ||
*Cladribine | * Preffered ones: | ||
*Imatinib | **1. [[Hydroxyurea]]:<ref name="ElliottHanson2004">{{cite journal|last1=Elliott|first1=M A|last2=Hanson|first2=C A|last3=Dewald|first3=G W|last4=Smoley|first4=S A|last5=Lasho|first5=T L|last6=Tefferi|first6=A|title=WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature|journal=Leukemia|volume=19|issue=2|year=2004|pages=313–317|issn=0887-6924|doi=10.1038/sj.leu.2403562}}</ref><ref name="ElliottPardanani2015">{{cite journal|last1=Elliott|first1=Michelle A.|last2=Pardanani|first2=Animesh|last3=Hanson|first3=Curtis A.|last4=Lasho|first4=Terra L.|last5=Finke|first5=Christy M.|last6=Belachew|first6=Alem A.|last7=Tefferi|first7=Ayalew|title=ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia|journal=American Journal of Hematology|volume=90|issue=7|year=2015|pages=653–656|issn=03618609|doi=10.1002/ajh.24031}}</ref><ref>{{cite web|url=http://packageinserts.bms.com/pi/pi_hydrea.pdf|title=Hydrea (Hydroxyurea Package Insert)}}</ref> | ||
***Preferred regimen: 20-30 mg/kg PO as a single dose daily, for 6 weeks | |||
***'''Note (1)''': [[Hydroxyurea]] is the most effective drug in controlling of leukocytosis and splenomegaly | |||
***'''Note (2):''' [[Hydroxyurea]] is used before progressive or [[blast]] transformation stages | |||
**2. [[Ruxolitinib]] : Based on the role of [[Ruxolitinib]] on [[JAK-STAT pathway]] and this pathway is also had role in [[pathogenesis]] of CNL, it can be used in treatment of [[patients]] with CNL.<ref name="SzuberTefferi2018" /><ref>{{Cite journal | |||
| author = [[Leah Wolfe]] | |||
| title = Ruxolitinib in Myelofibrosis and Polycythemia Vera | |||
| journal = [[Journal of the advanced practitioner in oncology]] | |||
| volume = 7 | |||
| issue = 4 | |||
| pages = 436–444 | |||
| year = 2016 | |||
| month = May-June | |||
| pmid = 29226001 | |||
}}</ref> | |||
***Preferred regimen in [[Myeloproliferative disease|myeloproliferative disorders]] based on [[platelet count]]: | |||
****Greater than 200×10<sup>9</sup>/L: 20 mg PO q12h | |||
****100 to 200×10<sup>9</sup>/L: 15 mg PO q12h | |||
****50 to less than 100×10<sup>9</sup>/L: 5 mg PO q12h | |||
***'''Note (1) :''' Monitoring of [[complete blood counts]] every 2 to 4 weeks should be done until doses are stabilized. | |||
*Alternative ones: | |||
**1.[[Interferon]] : IFN-α is used in some [[patients]] but the [[result]] of responding to this drug was not equal.<ref>{{Cite journal | |||
| author = [[M. A. Elliott]], [[G. W. Dewald]], [[A. Tefferi]] & [[C. A. Hanson]] | |||
| title = Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study | |||
| journal = [[Leukemia]] | |||
| volume = 15 | |||
| issue = 1 | |||
| pages = 35–40 | |||
| year = 2001 | |||
| month = January | |||
| pmid = 11243396 | |||
}}</ref> | |||
**2.[[Thalidomide]] | |||
**3.[[Cladribine]] | |||
**4.[[Imatinib]] | |||
==References== | ==References== | ||
| Line 17: | Line 51: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | |||
Latest revision as of 20:57, 29 July 2020
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia medical therapy |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
There is no standard medical treatment for chronic neutrophilic leukemia (CNL). Although, Hydroxyurea, Ruxolitinib, Interferon, Thalidomide, Cladribine and Imatinib are some options that are used in patients with CNL.
|
Chronic neutrophilic leukemia Microchapters |
|
Differentiating Chronic neutrophilic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic neutrophilic leukemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Chronic neutrophilic leukemia medical therapy |
|
Directions to Hospitals Treating Chronic neutrophilic leukemia |
|
Risk calculators and risk factors for Chronic neutrophilic leukemia medical therapy |
Medical Therapy
There is no established treatment for patients with CNL. However, following options may be useful in treatment of patients with CNL:[1][2][3]
- Preffered ones:
- 1. Hydroxyurea:[1][4][5]
- Preferred regimen: 20-30 mg/kg PO as a single dose daily, for 6 weeks
- Note (1): Hydroxyurea is the most effective drug in controlling of leukocytosis and splenomegaly
- Note (2): Hydroxyurea is used before progressive or blast transformation stages
- 2. Ruxolitinib : Based on the role of Ruxolitinib on JAK-STAT pathway and this pathway is also had role in pathogenesis of CNL, it can be used in treatment of patients with CNL.[2][6]
- Preferred regimen in myeloproliferative disorders based on platelet count:
- Greater than 200×109/L: 20 mg PO q12h
- 100 to 200×109/L: 15 mg PO q12h
- 50 to less than 100×109/L: 5 mg PO q12h
- Note (1) : Monitoring of complete blood counts every 2 to 4 weeks should be done until doses are stabilized.
- Preferred regimen in myeloproliferative disorders based on platelet count:
- 1. Hydroxyurea:[1][4][5]
- Alternative ones:
- 1.Interferon : IFN-α is used in some patients but the result of responding to this drug was not equal.[7]
- 2.Thalidomide
- 3.Cladribine
- 4.Imatinib
References
- ↑ 1.0 1.1 Elliott, M A; Hanson, C A; Dewald, G W; Smoley, S A; Lasho, T L; Tefferi, A (2004). "WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature". Leukemia. 19 (2): 313–317. doi:10.1038/sj.leu.2403562. ISSN 0887-6924.
- ↑ 2.0 2.1 Szuber, Natasha; Tefferi, Ayalew (2018). "Chronic neutrophilic leukemia: new science and new diagnostic criteria". Blood Cancer Journal. 8 (2). doi:10.1038/s41408-018-0049-8. ISSN 2044-5385.
- ↑ You W, Weisbrot IM (1979). "Chronic neutrophilic leukemia. Report of two cases and review of the literature". Am J Clin Pathol. 72 (2): 233–42. PMID 289288.
- ↑ Elliott, Michelle A.; Pardanani, Animesh; Hanson, Curtis A.; Lasho, Terra L.; Finke, Christy M.; Belachew, Alem A.; Tefferi, Ayalew (2015). "ASXL1mutations are frequent and prognostically detrimental inCSF3R-mutated chronic neutrophilic leukemia". American Journal of Hematology. 90 (7): 653–656. doi:10.1002/ajh.24031. ISSN 0361-8609.
- ↑ "Hydrea (Hydroxyurea Package Insert)" (PDF).
- ↑ Leah Wolfe (2016). "Ruxolitinib in Myelofibrosis and Polycythemia Vera". Journal of the advanced practitioner in oncology. 7 (4): 436–444. PMID 29226001. Unknown parameter
|month=ignored (help) - ↑ M. A. Elliott, G. W. Dewald, A. Tefferi & C. A. Hanson (2001). "Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study". Leukemia. 15 (1): 35–40. PMID 11243396. Unknown parameter
|month=ignored (help)